-
公开(公告)号:US20230159891A1
公开(公告)日:2023-05-25
申请号:US17915940
申请日:2021-03-30
Applicant: Kyoto University , TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Shin KANEKO , Shoichi IRIGUCHI
IPC: C12N5/0783 , A61K35/17
CPC classification number: C12N5/0636 , A61K35/17 , C12N2506/45 , C12N2500/02 , C12N2501/155 , C12N2501/115 , C12N2501/165 , C12N2501/2303 , C12N2501/2306 , C12N2501/2307
Abstract: The following are disclosed: a method for producing a T cell progenitor, including step (1) of culturing CD34+ cell in a medium containing an aryl hydrocarbon receptor antagonist, a medium for T cell progenitor differentiation containing an aryl hydrocarbon receptor antagonist, and a T cell progenitor inducer containing an aryl hydrocarbon receptor antagonist.
-
公开(公告)号:US20230000915A1
公开(公告)日:2023-01-05
申请号:US17778611
申请日:2020-11-24
Applicant: Kyoto University , Takeda Pharmaceutical Company Limited
Inventor: Shin KANEKO , Suguru ARIMA , Maiko TAKIGUCHI , Yoshiaki KASSAI , Akira HAYASHI
IPC: A61K35/17 , C12N5/0783 , C12N15/62 , C12N15/86 , C07K14/725 , C07K14/705 , A61P35/00
Abstract: The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.
-
公开(公告)号:US20220411752A1
公开(公告)日:2022-12-29
申请号:US17773467
申请日:2020-10-30
Applicant: Kyoto University , Takeda Pharmaceutical Company Limited
Inventor: Shin KANEKO , Hisashi YANO , Tokuyuki SHINOHARA
IPC: C12N5/0783 , C12N15/90
Abstract: Provided is an excellent method for producing an IL-4 non-secreting and IFN-γ secreting (Th1-type) or IFN-γ non-secreting and IL-4 secreting (Th2-type) CD4 single-positive T cell (CD4SP T cell). The method for producing the Th1-type or Th2-type CD4SP T cell of the present invention comprises a step of inducing a CD4 single-positive T cell from a hematopoietic stem cell (HSC) and/or a hematopoietic progenitor cell (HPC) substantially defective in a factor involved in IL-4 secretion or a factor involved in IFN-γ secretion.
-
公开(公告)号:US20220099670A1
公开(公告)日:2022-03-31
申请号:US17427222
申请日:2021-01-31
Applicant: Kyoto University , TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Shin KANEKO , Shoichi IRIGUCHI , Keiko SEKIYA , Yoshiaki KASSAI
IPC: G01N33/567 , C12N5/00 , C12N5/0784 , G01N33/50
Abstract: Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.
-
公开(公告)号:US20240400993A1
公开(公告)日:2024-12-05
申请号:US18695720
申请日:2022-09-26
Applicant: Kyoto University , TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Shin KANEKO , Shoichi IRIGUCHI , Yoshiaki KASSAI , Keiko SEKIYA , Atsushi MATSUDA , Takayuki SATO
IPC: C12N5/0783 , A61K35/17
Abstract: Disclosed is a method for producing regulatory T cells, the method comprising: (1) differentiating cells that can differentiate into regulatory T cells, into which an expression construct is introduced, into regulatory T cells, the expression construct comprising: (a) conserved non-coding sequence (CNS) 1, CNS2, and CNS3 of Foxp3 gene; (b) a promoter; and (c) a nucleic acid encoding FOXP3. Also disclosed are regulatory T cells obtained by the method, and a pharmaceutical composition comprising the regulatory T cells.
-
公开(公告)号:US20220089672A1
公开(公告)日:2022-03-24
申请号:US17416859
申请日:2019-12-26
Applicant: Kyoto University , Takeda Pharmaceutical Company Limited
Inventor: Shin KANEKO , Yoshiaki KASSAI , Akira HAYASHI
IPC: C07K14/725 , C12N15/86
Abstract: The present invention provides a variant of a T-cell receptor containing a combination of two polypeptides containing a constant region of a T cell receptor chain selected from the group consisting of α chain, β chain, γ chain and δ chain, wherein the polypeptide does not contain a complementarity determining region (CDR) of the T cell receptor chain, a complementarity determining region (CDR) of the α chain, and a complementarity determining region (CDR) of the β chain.
-
公开(公告)号:US20250129075A1
公开(公告)日:2025-04-24
申请号:US18938232
申请日:2024-11-05
Applicant: KIRIN HOLDINGS KABUSHIKI KAISHA, , Kyoto University
Inventor: Shinichiro TAKAYANAGI , Atsushi KUNISATO , Sayaka CHUGANJI , Ken FUKUMOTO , Kazuki NAKAZONO , Shin KANEKO , Yohei KAWAI
IPC: C07D471/18 , C07D215/00 , C07D217/22 , C12N5/0783
Abstract: An object of the present invention is to provide a method for producing T cells or NK cells, a culture medium for culturing T cells or NK cells, a method for culturing T cells or NK cells, a method for maintaining the undifferentiated state of undifferentiated T cells, and a growth promoter for T cells or NK cells, which are capable of efficiently proliferating T cells or NK cells and maintaining the state of the cells (for example, undifferentiated property).
The present invention relates to a method for producing T cells or NK cells including culturing T cells or NK cells in a culture medium containing a bisbenzylisoquinoline alkaloid represented by formula (X-1) or formula (X-2) or a compound resulting from cleavage of one ether bond thereof or a pharmaceutically acceptable salt thereof, and the like.-
公开(公告)号:US20240294871A1
公开(公告)日:2024-09-05
申请号:US18656496
申请日:2024-05-06
Applicant: KYOTO UNIVERSITY
Inventor: Shin KANEKO , Yohei KAWAI
IPC: C12N5/0783 , A61K35/17 , C12N5/00 , C12N5/074
CPC classification number: C12N5/0638 , A61K35/17 , C12N5/0018 , C12N5/0696 , C12N2500/38 , C12N2501/2307 , C12N2501/2312 , C12N2501/2315 , C12N2501/2318 , C12N2501/2321 , C12N2501/26 , C12N2501/42 , C12N2501/50 , C12N2501/998 , C12N2506/45 , C12N2533/52
Abstract: A method efficiently produces cytotoxic T lymphocytes having intrinsic properties of lymphocytes of the acquired immune system suitable for cellular immunotherapy. The method includes culturing CD4/CD8 double-positive T cells in a medium containing IL-7 and a T-cell receptor activator, to induce CD8α+β+ cytotoxic T lymphocytes.
-
公开(公告)号:US20230257705A1
公开(公告)日:2023-08-17
申请号:US18002009
申请日:2021-06-16
Applicant: KYOTO UNIVERSITY
Inventor: Shin KANEKO , Tatsuki UEDA
IPC: C12N5/0783 , C07K14/54 , A61K35/17 , A61P35/00
CPC classification number: C12N5/0636 , C07K14/5443 , A61K35/17 , A61P35/00 , C07K2319/03 , C07K2319/32 , C07K2319/74
Abstract: The present invention aims to increase cytotoxic activity of an immunocompetent cell to thereby enhance a therapeutic effect against diseases such as cancers, and provides an immunocompetent cell having decreased diacylglycerol kinase activity, which cell expresses a fusion protein including IL-15 and an IL-15 receptor α subunit, and which cell expresses a chimeric antigen receptor.
-
公开(公告)号:US20220017867A1
公开(公告)日:2022-01-20
申请号:US17311001
申请日:2019-12-06
Applicant: KIRIN HOLDINGS KABUSHIKI KAISHA , Kyoto University
Inventor: Shinichiro TAKAYANAGI , Atsushi KUNISATO , Sayaka CHUGANJI , Ken FUKUMOTO , Kazuki NAKAZONO , Shin KANEKO , Yohei KAWAI
IPC: C12N5/0783 , C07D471/18
Abstract: An object of the present invention is to provide a method for producing T cells or NK cells, a culture medium for culturing T cells or NK cells, a method for culturing T cells or NK cells, a method for maintaining the undifferentiated state of undifferentiated T cells, and a growth promoter for T cells or NK cells, which are capable of efficiently proliferating T cells or NK cells and maintaining the state of the cells (for example, undifferentiated property).
The present invention relates to a method for producing T cells or NK cells including culturing T cells or NK cells in a culture medium containing a bisbenzylisoquinoline alkaloid represented by formula (X-1) or formula (X-2) or a compound resulting from cleavage of one ether bond thereof or a pharmaceutically acceptable salt thereof, and the like.
-
-
-
-
-
-
-
-
-